|Bid||0.00 x 1200|
|Ask||0.00 x 2200|
|Day's Range||87.93 - 92.69|
|52 Week Range||41.51 - 98.84|
|Beta (5Y Monthly)||2.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||90.43|
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In 2002 Asaf Danziger was appointed CEO of NovoCure Limited (NASDAQ:NVCR). This analysis aims first to contrast CEO...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories ...
Novocure stock broke out of a cup-with-handle base Tuesday after the company's cancer treatment device, dubbed Optune, gained insurance coverage in Israel for newly diagnosed glioblastoma.
Novocure announced national reimbursement in Israel for Optune® in combination with temozolomide for the treatment of newly diagnosed glioblastoma.
The major stock indexes were squarely higher Friday morning, as they set more record highs. Dow Jones stock Home Depot offers a new buy point.
Novocure is the IBD Stock Of The Day as shares of the cancer treatment specialist break out of a double-bottom chart pattern following a strong preliminary fourth-quarter sales report.
Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2019.
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first patient has been enrolled in a phase 2 pilot clinical trial evaluating the safety and efficacy of Tumor Treating Fields in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. “Zai Lab licensed Tumor Treating Fields from Novocure in September 2018, and we have since launched Optune® in Hong Kong for the treatment of patients with recurrent, or newly diagnosed glioblastoma multiforme (GBM) and submitted a Marketing Authorization Application to the China National Medical Products Administration (NMPA) for approval,” said Dr. Samantha Du, Founder and CEO of Zai Lab.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
SANTA CLARA, Calif., Dec. 04, 2019 -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the.
NovoCure Ltd. was favored by Jim Cramer during the Lightning Round segment of " Mad Money" Tuesday night. In this daily bar chart of NVCR, below, we can see that prices took about two months to decline in September and October, but retraced nearly that entire decline in just one month. This movement is not an indicator, but I consider this observation a sign of strength in that prices have gone up faster than they went down.
Medical stocks look like the early leaders of this market advance, and Novocure (NVCR) is one that had a nice run earlier this year and is now shaping up a great-looking launching pad, explains growth stock expert Mike Cintolo, editor of Cabot Top Ten Trader.
The downside correction in NovoCure looks like it has run its course. NVCR is looking ready to resume its uptrend. In this daily bar chart of NVCR, below, it looks like prices are bottoming again after a declining phase from late August.
NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?